Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

PHASE3TerminatedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Diabetic Foot Ulcer
Interventions
DRUG

0.03% DSC127 topical gel

Trial Locations (21)

17402

Martin Foot & Ankle, York

24016

Professional Education and Research Institute, Roanoke

27834

Eastern Carolina Foot & Ankle Specialists, Greenville

28411

O'Malley Foot and Ankle, Wilmington

29801

Carolina Musculoskeletal Institute, Aiken

32209

UF Health Orthopaedic Surgery Clinic, Jacksonville

33016

GF Professional Research, Miami Lakes

33030

Advanced Research Institute of Miami, Homestead

33165

Phoenix Medical Research, LLC, Miami

33169

Barry University Clinical Research, North Miami Beach

33176

Miami Dade Medical Research Institute, Miami

33713

Professional Health Care of Pinellas, St. Petersburg

36608

WILMAX Clinical Research, Mobile

78229

Endeavor Clinical Trials, San Antonio

90010

Foot and Ankle Clinic, Los Angeles

91342

Olive View - UCLA Medical Center, Sylmar

91710

Reliance Institute of Clinical Research, Chino

92780

Orange County Research Center, Tustin

93710

Roy O. Kroeker, DMP, Inc., Fresno

93720

Limb Preservation Platform (LPP), Fresno

94115

Center for Clinical Research, Inc., San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

Integra LifeSciences Corporation

INDUSTRY

NCT01840085 - Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use | Biotech Hunter | Biotech Hunter